“Graft-versus-host disease (GVHD) occurs due to complications of allogeneic hematopoietic stem cell transplant,” Nicole B. Kantor, BS, from Bascom Palmer Eye Institute, and colleagues wrote.

2. Zeiser R, Blazar BR. Acute graft-versus-host disease — biologic process, prevention, and therapy. N Engl J Med 2017;377:2167-2179.

Ask your doctor about regulating certain foods and supplements that can increase disease severity. Be intentional about your strategy to manage GVHD through your diet. EDITORIAL SOURCES ...

Ocular Graft-versus-Host Disease, an orphan condition impacting roughly 50,000 patients annually in the United States, currently has no FDA-approved treatment. Pro-ocular has demonstrated its ...

Orca-T, a T-cell immunotherapy, significantly improved survival free of moderate-to-severe chronic graft-versus-host disease (cGvHD) compared with allogeneic hematopoietic stem cell transplant ...

Axatilimab in Chronic Graft-versus-Host Disease Results A total of 241 patients were enrolled (80 patients in the 0.3-mg dose group, 81 in the 1-mg dose group, and 80 in the 3-mg dose group).

Graft-versus-host disease (GVHD) following liver transplantation remains a rare but devastating complication, characterised by donor immunocompetent cells initiating an immune attack against host ...

FDA approves Mesoblast's Ryoncil, the first U.S. MSC therapy, for children with steroid-refractory acute graft-versus-host disease. In a Phase 3 trial, 70% of SR-aGvHD patients responded to ...